Financing - December 16, 2014
BenGenBio Raises NOK90 Million
BerGenBio AS, a Norwegian biopharmaceutical company focused on developing medications for aggressive drug- resistant cancers, announced that it has raised NOK90 million (c. $15 million) in a private placing from new and existing investors. BerGenBio will use the proceeds from the financing to support the development of its pipeline of innovative cancer therapeutics, in particular an enlarged […]
Financing - January 24, 2014
Cantargia receives capital injection
Cantargia, a private biopharmaceutical company developing therapeutics for the treatment of leukemia has announced the conclusion of the first step in their financial plan and reinforces the board. Sven Andréasson has been appointed as chairman of the board. Sven Andréasson has extensive experience in both pharmaceutical and biotech companies. He was CEO of Active Biotech […]